Abbott Laboratories will pay $385 million to settle legal claims arising from investigations into contamination at its infant formula manufacturing plant in Sturgis, Michigan. This plant, the largest infant formula manufacturing facility in the United States, was shut down in 2022 due to health concerns and contamination, leading to severe shortages of this product in the market.
Impacts and Legal Claims
Concerns about this facility led to a lawsuit from the Department of Justice and a widespread recall of powdered formula products. This recall affected several major product lines, including Similac, and further strained existing inventories that were already pressured by supply chain issues and stockpiling during COVID-19-related shutdowns.
Read more: Fighting HIV stigma in the community
Settlement Details and Investigations
This settlement includes legal claims filed by specific representatives as well as attorneys general from several states, although Abbott has stated that this agreement does not include any findings of fault or liability. Abbott announced on Monday that regulatory tests on unopened formulas taken from homes of infants examined during the 2022 recall were negative for the Cronobacter sakazakii bacteria. The company also emphasized that no Abbott formula that was distributed unpackaged has ever tested positive for this bacteria.
Criminal investigations into this matter, conducted by the Department of Justice under Donald Trump, have recently concluded. To address the infant formula shortage, the Biden administration eased import regulations for foreign manufacturers, airlifted formula from Europe to the United States, and implemented emergency federal regulations to prioritize domestic production.
Abbott closed the Sturgis plant in February 2022 after the FDA began its investigation and reopened it in June of the same year.
Read more: Living with tinnitus: How can it be endured? · City embroiled in pigeon dirt controversy on Main Street
Source: independent.co.uk
